Last updated on March 2020

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

Brief description of study

This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.

Clinical Study Identifier: NCT02141074

Find a site near you

Start Over

Novo Nordisk Investigational Site

St. Poelten, Austria
  Connect »